Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer

Gene Therapy

Volumn 13, Issue 7, 2006, Pages 587-593

  Ding, Z ^a   Georgiev, P ^b   Thöny, Beat ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Adeno associated virus 8; Hyperphenylalaninemia; Liver; Phenylalanine hydroxylase; Phenylketonuria

Indexed keywords

COMPLEMENTARY DNA; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; ENZYME ACTIVITY; FEASIBILITY STUDY; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; HYPERPHENYLALANINEMIA; IMMUNOGENICITY; LENTIVIRUS VECTOR; LIVER TOXICITY; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PARVOVIRUS VECTOR; PHENOTYPE; PHENYLKETONURIA; PRIORITY JOURNAL; SEROTYPE; SEX DIFFERENCE; SOMATIC GENE THERAPY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID;

ANIMALS; ANTIBODIES, MONOCLONAL; DEPENDOVIRUS; DNA, RECOMBINANT; FEMALE; GENE THERAPY; GENETIC VECTORS; HAIR COLOR; INJECTIONS, INTRAVENOUS; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MODELS, ANIMAL; PHENYLALANINE; PHENYLALANINE HYDROXYLASE; PHENYLKETONURIAS; PORTAL VEIN; SEX FACTORS; TAIL; TRANSDUCTION, GENETIC;

ADENO-ASSOCIATED VIRUS; ADENO-ASSOCIATED VIRUS - 8; ANIMALIA; LENTIVIRUS; MIRIDAE; MURINAE; PARVOVIRUS;

EID: 33645098770     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302684     Document Type: Article

References (47)

1. Scriver CR, Hurtubise M, Konecki D, Phommarinh M, Prevost L, Erlandsen H et al. PAHdb 2003: What a locus-specific knowledgebase can do. Hum Mutat 2003; 21: 333-344.
2. Scriver CR, Eisensmith RC, Woo SL, Kaufman S. The hyperphenylalaninemias of man and mouse. Annu Rev Genet 1994; 28: 141-165.
3. Howell RR, Chakravarti A, Dawson G, Dungy CI, Fletcher JM, Jackson D et al. National Institutes of Health Consensus Development Conference Statement: Shenylketonuria: screening and management, October 16-18, 2000. Pediatrics 2001; 108: 972-982.
4. Alexander D. The National Institute of Child Health and Human Development and phenylketonuria. Pediatrics 2003; 112: 1514-1515.
5. Merrick J, Aspler S, Schwarz G. Phenylalanine-restricted diet should be life long. A case report on long-term follow-up of an adolescent with untreated phenylketonuria. Int J Adolesc Med Health 2003; 15: 165-168.
6. Harding CO. 'Mommy, why can't I have a hamburger like the other kids?'. Gene Therapy 2000; 7: 1969-1970.
7. Smith I, Lobascher ME, Stevenson JE, Wolff OH, Schmidt H, Grubel-Kaiser S et al. Effect of stopping low-phenylalanine diet on intellectual progress of children with phenylketonuria. Br Med J 1978; 2: 723-726.
8. Koch R, Burton B, Hoganson G, Peterson R, Rhead W, Rouse B et al. Phenylketonuria in adulthood: A collaborative study. J Inherit Metab Dis 2002; 25: 333-346.
9. Guttler F, Azen C, Guldberg P, Romstad A, Hanley WB, Levy HL et al. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome. Pediatrics 2003; 112: 1530-1533.
10. Kootstra NA, Verma IM. Gene therapy with viral vectors. Annu Rev Pharmacol Toxicol 2003; 43: 413-439.
11. Grimm D, Zhou S, Nakai H, Thomas CE, Storm TA, Fuess S et al. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 2003; 102: 2412-2419.
12. Sarkar R, Tetreault R, Gao G, Wang L, Bell P, Chandler R et al. Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 2004; 103: 1253-1260.
13. Arruda VR, Stedman HH, Nichols TC, Haskins ME, Nicholson M, Herzog RW et al. Regional intravascular delivery of AAV-2-F. IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. Blood 2005; 105: 3458-3464.
14. Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med 2004; 10: 828-834.
15. Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. J Gene Med 2005; 7: 442-451.
16. Glatzel M, Flechsig E, Navarro B, Klein MA, Paterna JC, Bueler H et al. Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system. Proc Natl Acad Sci USA 2000; 97: 442-447.
17. Paterna JC, Feldon J, Bueler H. Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J Virol 2004; 78: 6808-6817.
18. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet 2000; 24: 257-261.
19. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003; 101: 2963-2972.
20. Wagner JA, Nepomuceno IB, Messner AH, Moran ML, Batson EP, Dimiceli S et al. A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies. Hum Gene Ther 2002; 13: 1349-1359.
21. Flotte TR, Zeitlin PL, Reynolds TC, Heald AE, Pedersen P, Beck S et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: A two-part clinical study. Hum Gene Ther 2003; 14: 1079-1088.
22. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854-11859.
23. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Therapy 1999; 6: 1574-1583.
24. Nakai H, Thomas CE, Storm TA, Fuess S, Powell S, Wright JF. A limited number of transducible hepatocytes restricts a wide-range linear vector dose response in recombinant adeno-associated virus-mediated liver transduction. J Virol 2002; 76: 11343-11349.
25. Nakai H, Fuess S, Storm TA, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005; 79: 214-224.
26. Ding Z, Harding CO, Thöny B. State-of-the-art 2003 on PKU gene therapy. Mol Genet Metab 2004; 81: 3-8.
27. Mochizuki S, Mizukami H, Ogura T, Kure S, Ichinohe A, Kojima K et al. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice. Gene Therapy 2004; 11: 1081-1086.
28. Oh HJ, Park ES, Kang S, Jo I, Jung SC. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer. Pediatr Res 2004; 56: 278-284.
29. McDonald JD, Bode VC, Dove WF, Shedlovsky A. Pahhph-5: A mouse mutant deficient in phenylalanine hydroxylase. Proc Natl Acad Sci USA 1990; 87: 1965-1967.
30. McDonald JD, Andriolo M, Cali F, Mirisola M, Puglisi-Allegra S, Romano V et al. The phenylketonuria mouse model: A meeting review. Mol Genet Metab 2002; 76: 256-261.
31. Thöny B, Ding Z, Martinez A. Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: Implications for tetrahydrobiopterin-responsive hyperphenylalaninemia. FEBS Lett 2004; 577: 507-511.
32. Ledley FD, Grenett HE, Woo SL. Biochemical characterization of recombinant human phenylalanine hydroxylase produced in Escherichia coli. J Biol Chem 1987; 262: 2228-2233.
33. Paterna JC, Moccetti T, Mura A, Feldon J, Bueler H. Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Therapy 2000; 7: 1304-1311.
34. McDonald JD, Charlton CK. Characterization of mutations at the mouse phenylalanine hydroxylase locus. Genomics 1997; 39: 402-405.
35. Fang B, Eisensmith RC, Li XH, Finegold MJ, Shedlovsky A, Dove W et al. Gene therapy for phenylketonuria: Phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Therapy 1994; 1: 247-254.
36. Nagasaki Y, Matsubara Y, Takano H, Fujii K, Senoo M, Akanuma J et al. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Pediatr Res 1999; 45: 465-473.
37. Lizee G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, Topalian SL. Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum Gene Ther 2003; 14: 497-507.
38. Bell P, Wang L, Lebherz C, Flieder DB, Bove MS, Wu D et al. No evidence for tumorigenesis of AAV vectors in a large-scale study in mice. Mol Ther 2005; 12: 299-306.
39. Kingsman SM, Mitrophanous K, Olsen JC. Potential oncogene activity of the woodchuck hepatitis post-transcriptional regulatory element (WPRE). Gene Therapy 2005; 12: 3-4.
40. Davidoff AM, Ng CY, Zhou J, Spence Y, Nathwani AC. Sex significantly influences transduction of murine liver by recombinant adeno-associated viral vectors through an androgen-dependent pathway. Blood 2003; 102: 480-488.
41. Nguyen TH, Ferry N. Liver gene therapy: Advances and hurdles. Gene Therapy 2004; 11 (Suppl 1): S76-S84.
42. Prieto J, Qian C, Hernandez-Alcoceba R, Gonzalez-Aseguinolaza G, Mazzolini G, Sangro B et al. Gene therapy of liver diseases. Expert Opin Biol Ther 2004; 4: 1073-1091.
43. Harding CO, Wild K, Chang D, Messing A, Wolff JA. Metabolic engineering as therapy for inborn errors of metabolism - development of mice with phenylalanine hydroxylase expression in muscle. Gene Therapy 1998; 5: 677-683.
44. Haberman RP, Kroner-Lux G, Samulski RJ. Production of adeno-associated viral vectors. Current Protocols in Human Genetics 1999, 12.9.1-12.9.17.
45. Potter M, Chesnut K, Muzyczka N, Flotte T, Zolotukhin S. Streamlined large-scale production of recombinant adeno-associated virus (rAAV) vectors. Methods Enzymol 2002; 346: 413-430.
46. van Til NP, Markusic DM, van der Rijt R, Kunne C, Hiralall JK, Vreeling H et al. Kupffer cells and not liver sinusoidal endothelial cells prevent lentiviral transduction of hepatocytes. Mol Ther 2005; 11: 26-34.
47. Cresawn KO, Fraites TJ, Wasserfall C, Atkinson M, Lewis M, Porvasnik S et al. Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II. Hum Gene Ther 2005; 16: 68-80.